• Clinical Trials - Macular Degeneration

    Study Objective Contact
    A Pilot Investigation of Dark Adaptation Following Intravitreal Injection of anti-VEGF Agents [LCID Study Number: 2015-020] The purpose of this study is to determine if treatment with medications targeting vascular endothelial growth factor (VEGF) (e.g. bevacizumab, ranibizumab, and aflibercept) improves the ability of patients with age-related macular degeneration, diabetic macular edema, or a central retinal vein occlusion with macular edema to adjust from light to dark conditions (i.e. dark adaptation). Patients being treated for the above conditions with a standard VEGF medication will be tested over 4 months for their ability to adjust from light to dark before and after being treated. In addition, healthy volunteers will participate so that dark adaptation information from both groups can be compared to look for differences in testing data. Principal Investigator(s):
    David J. Ramsey, MD, PhD, MPH

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Christine A. Gould, MMSc, PAC.
    Protocol OPH1003: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™(anti PDGF-b pegylated aptamer) Administered in Combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration [LCID Study Number: 2013-066] The objectives of this study are to evaluate the safety and efficacy of an investigational drug Fovista„§ when administered in combination with the FDA-approved drug Lucentis„¥ compared to Lucentis„¥ alone in patients with abnormal blood vessels in the back of the eye due to wet age-related macular degeneration (AMD). Both Fovista„§ and Lucentis„¥ are given by injection into the vitreous which is the clear, jelly-like substance that fills the middle of the eye. Principal Investigator(s):
    Gregory R. Blaha, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Christine A. Gould, MMSc, PAC.